FDA Inspection 1229895 — Eli Lilly & Company
The FDA completed an inspection of Eli Lilly & Company on January 15, 2025 in Indianapolis, IN. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- January 15, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Indianapolis, IN (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)